September 2, 2018

Al Hammadi Announces the latest developments of the Memorandum of Understanding (MOU) signed with Sudair Pharma Company

In reference to the announcement of Al Hammadi Company for Development and Investment published on Tadawul website on 10/10/1439H corresponding to 24/06/2018G regarding the extension of the Memorandum of Understanding (MOU) signed on April 21, 2018 with Sudair Pharma Company for the acquisition of an equity stake with the same terms and conditions until August 31, 2018. Al Hammadi announces that the Memorandum of Understanding (MOU) with Sudair Pharma has expired and will not be renewed due to the failure to reach a final agreement on some terms in Partners Agreement.

The Capital Market Authority and the Saudi Stock Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.